NeoPharm Current Valuation vs. Total Debt
| 092730 Stock | KRW 11,860 120.00 1.00% |
For NeoPharm profitability analysis, we use financial ratios and fundamental drivers that measure the ability of NeoPharm to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well NeoPharm LTD utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between NeoPharm's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of NeoPharm LTD over time as well as its relative position and ranking within its peers.
NeoPharm |
NeoPharm LTD Total Debt vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining NeoPharm's current stock value. Our valuation model uses many indicators to compare NeoPharm value to that of its competitors to determine the firm's financial worth. NeoPharm LTD is the top company in current valuation category among its peers. It also is the top company in total debt category among its peers . The ratio of Current Valuation to Total Debt for NeoPharm LTD is about 1,509 . Comparative valuation analysis is a catch-all model that can be used if you cannot value NeoPharm by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for NeoPharm's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.NeoPharm Current Valuation vs. Competition
NeoPharm LTD is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Consumer Staples industry is presently estimated at about 44.87 Trillion. NeoPharm adds roughly 153.58 Billion in current valuation claiming only tiny portion of stocks in Consumer Staples industry.
NeoPharm Total Debt vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
NeoPharm |
| = | 153.58 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
NeoPharm |
| = | 101.79 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
NeoPharm Total Debt vs Competition
NeoPharm LTD is the top company in total debt category among its peers. Total debt of Consumer Staples industry is presently estimated at about 69.22 Trillion. NeoPharm adds roughly 101.79 Million in total debt claiming only tiny portion of stocks in Consumer Staples industry.
NeoPharm Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in NeoPharm, profitability is also one of the essential criteria for including it into their portfolios because, without profit, NeoPharm will eventually generate negative long term returns. The profitability progress is the general direction of NeoPharm's change in net profit over the period of time. It can combine multiple indicators of NeoPharm, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
,Ltd. manufactures and sells skin care products in Korea and internationally. ,Ltd. was founded in 2000 and is headquartered in Daejeon, South Korea. Neopharm is traded on Korean Securities Dealers Automated Quotations in South Korea.
NeoPharm Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on NeoPharm. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of NeoPharm position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the NeoPharm's important profitability drivers and their relationship over time.
Use NeoPharm in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NeoPharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeoPharm will appreciate offsetting losses from the drop in the long position's value.NeoPharm Pair Trading
NeoPharm LTD Pair Trading Analysis
The ability to find closely correlated positions to NeoPharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NeoPharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NeoPharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NeoPharm LTD to buy it.
The correlation of NeoPharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NeoPharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NeoPharm LTD moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NeoPharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your NeoPharm position
In addition to having NeoPharm in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Impulse Thematic Idea Now
Impulse
Large corporations operating in retail, broadcasting, energy, airlines and telecom sectors. The Impulse theme has 49 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Impulse Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in NeoPharm Stock
To fully project NeoPharm's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of NeoPharm LTD at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include NeoPharm's income statement, its balance sheet, and the statement of cash flows.